References
- Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 2017;389:1885–1906
- Reitsma MB, Fullman N, Ng M, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 2017;389:1885-1906
- Ekpu VU, Brown AK. The economic impact of smoking and of reducing smoking prevalence: review of evidence. Tobacco Use Insights 2015;8:1-35
- Oh IH, Yoon SJ, Yoon TY, et al. Health and economic burden of major cancers due to smoking in Korea. Asian Pacific J Cancer Preven 2012;13:1525-31
- Kang H, Kim H, Park T, et al. Economic burden of smoking in Korea. Tob Cont 2003;12:37-44
- Berman M, Crane R, Seiber E, et al. Estimating the cost of a smoking employee. Tob Cont 2014;23:428-33
- Rasmussen SR, Prescott E, Sorensen TIA, et al. The total lifetime health cost savings of smoking cessation to society. Eur J Public Health 2005;15:601-6
- Weng SF, Ali S, Leonardi-Bee J. Smoking and absence from work: systematic review and meta-analysis of occupational studies. Addiction 2013;108:307-19
- Bockerman P, Hyytinen A, Kaprio J. Smoking and long-term labour market outcomes. Tob Cont 2015;24:348-53
- Halpern MTSR, Rentz AM, Khan ZM, et al. Impact of smoking status on workplace absenteeism and productivity. Tob Cont 2001;10:233-8
- Bunn WB 3rd, Stave GM, Downs KE, et al. Effect of smoking status on productivity loss. J Occup Environ Med 2006;48:1099-108
- Baker CL, Flores NM, Zou KH, et al. Benefits of quitting smoking on work productivity and activity impairment in the United States, the European Union and China. Int J Clin Pract 2017;71
- The National Institute for Health and Care Excellence (NICE). Varenicline for smoking cessation. NICE; 2007. London
- Jee SH, Samet JM, Ohrr H, et al. Smoking and cancer risk in Korean men and women. Cancer Causes Cont 2004;15:341-8
- Jee SH, Lee JM, Kim IS. Smoking-attributable mortality among Korean adults: 1981–2013. Kor J Epidemiol 2006;28:92-9
- Connolly MP, Kotsopoulos N, Postma MJ, et al. The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework. Value Health 2017;20:273-7
- Korean statistical information service. Household Income & Expenditure Trends in the Second Quarter 2011 [Internet]. KOSIS; 2011. Statistics Korea, Government Complex-Daejeon. http://kosis.kr/eng/
- Korean statistical information service. Korean unemployment rate by age group [Internet]. KOSIS; 2016. Statistics Korea, Government Complex-Daejeon. http://kosis.kr/eng/
- OECD. OECD Taxing Wages 2015. OECD; 2016. OECD Paris Cedex 16, France
- Korean statistical information service. Income tax rates [Internet]. KOSIS; 2016. Statistics Korea, Government Complex-Daejeon. http://kosis.kr/eng/
- Ministry of Strategy and Finance. Korean Taxation 2016. MoSF; 2016. Ministry Strategy and Finance, Sejong-si 30109, Korea
- Bae JY, Kim CH, Lee EK. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea. Value Health 2009;12(Suppl3):S70-S3
- Korean statistical information service. Consumer Price Index in March 2017 [Internet]. KOSIS; 2017. Statistics Korea, Government Complex-Daejeon kosis.kr/eng
- Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63
- Kwon S. Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage. Health Policy Plan 2009;24:63-71
- Song YJ. The South Korean health care system. JMAJ 2009;52:206-9
- Hind D, Tappenden P, Peters J, et al. Varenicline in the management of smoking cessation: a single technology appraisal. Health Technol Assess 2009;13(Suppl2):9-13
- Goodchild M, Nargis N, Tursan d’Espaignet E. Global economic cost of smoking-attributable diseases. Tob Control. 2018;27(1):58-64.
- Ahmad S, Franz GA. Raising taxes to reduce smoking prevalence in the US: a simulation of the anticipated health and economic impacts. Public Health 2008;122:3-10